Monoclonal antibodies provide protection against a wide range of infectious microbes, and now, in a series of elegant ...

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II trial has recently been ...

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and ...

In a prostate cancer mouse model (22Rv1 xenografts), the combination of 225 Ac-YS5 (0.12 µCi) + YS5-MMAE (1.8 mg/kg) was associated with the most significant reduction in tumor volume (green curves in ...

Two new drugs for Alzheimer’s have been rejected for use on the NHS. They slow progression of the disease, but they can have ...

Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 ...

Department of Chemistry, Hunter College of the City University of New York, New York, New York 10028, United States Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York ...

1Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, Canada. Search for other works by this author on: 1Department of Medical Imaging, College of Medicine, ...

Sacituzumab govitecan is an antibody-drug conjugate designed to direct a potent chemotherapy drug into cancer cells by targeting a protein called TROP-2 that is found on triple-negative breast ...

Objective Anti-NMDA receptor encephalitis is the most prevalent autoimmune encephalitis having characteristic clinical features with autoantibodies against tetrameric transmembrane channels composed ...

which shows the drug developer’s confidence in this drug. PM1022 is a bispecific antibody targeting PD-L1 and TIGIT, with VHH targeting PD-L1 fused to the C-terminus of the anti-TIGIT antibody. The ...